Mirova Has $5.14 Million Stake in Zoetis Inc. (NYSE:ZTS)

Mirova increased its stake in Zoetis Inc. (NYSE:ZTS - Free Report) by 76.1% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 31,570 shares of the company's stock after purchasing an additional 13,641 shares during the period. Mirova's holdings in Zoetis were worth $5,144,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of ZTS. Norges Bank acquired a new stake in Zoetis in the fourth quarter worth about $824,321,000. Wellington Management Group LLP grew its position in shares of Zoetis by 78.5% during the 4th quarter. Wellington Management Group LLP now owns 6,958,543 shares of the company's stock worth $1,133,755,000 after buying an additional 3,059,255 shares during the period. Raymond James Financial Inc. bought a new stake in shares of Zoetis during the fourth quarter worth approximately $196,651,000. Polen Capital Management LLC lifted its holdings in Zoetis by 17.5% in the fourth quarter. Polen Capital Management LLC now owns 7,483,194 shares of the company's stock valued at $1,219,237,000 after buying an additional 1,116,541 shares during the period. Finally, Capital Research Global Investors bought a new position in Zoetis in the fourth quarter valued at approximately $178,688,000. Institutional investors and hedge funds own 92.80% of the company's stock.

Wall Street Analysts Forecast Growth

ZTS has been the topic of several recent research reports. Barclays raised their price target on Zoetis from $242.00 to $244.00 and gave the stock an "overweight" rating in a research report on Friday, February 14th. Piper Sandler boosted their target price on Zoetis from $200.00 to $205.00 and gave the stock an "overweight" rating in a research report on Thursday, February 27th. Stifel Nicolaus cut their price target on shares of Zoetis from $180.00 to $165.00 and set a "buy" rating on the stock in a research report on Monday, April 14th. StockNews.com raised shares of Zoetis from a "hold" rating to a "buy" rating in a research note on Friday, March 7th. Finally, Morgan Stanley reduced their price target on shares of Zoetis from $243.00 to $238.00 and set an "overweight" rating on the stock in a research report on Friday, February 14th. One investment analyst has rated the stock with a hold rating, ten have issued a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of "Buy" and an average target price of $214.40.

Insider Activity

In other news, EVP Roxanne Lagano sold 326 shares of the stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $170.00, for a total transaction of $55,420.00. Following the transaction, the executive vice president now owns 15,781 shares in the company, valued at approximately $2,682,770. This trade represents a 2.02 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Willie M. Reed sold 1,210 shares of Zoetis stock in a transaction that occurred on Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total value of $201,029.40. Following the sale, the director now directly owns 11,245 shares of the company's stock, valued at approximately $1,868,244.30. The trade was a 9.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 1,862 shares of company stock valued at $312,254 over the last ninety days. 0.16% of the stock is currently owned by company insiders.

Zoetis Stock Performance

ZTS stock traded up $1.09 during trading hours on Wednesday, reaching $151.08. The stock had a trading volume of 2,093,141 shares, compared to its average volume of 2,522,362. The stock has a 50-day simple moving average of $159.19 and a 200 day simple moving average of $169.22. Zoetis Inc. has a fifty-two week low of $139.70 and a fifty-two week high of $200.33. The stock has a market capitalization of $67.41 billion, a PE ratio of 27.62, a price-to-earnings-growth ratio of 2.78 and a beta of 0.92. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.75 and a quick ratio of 1.08.

Zoetis (NYSE:ZTS - Get Free Report) last announced its quarterly earnings results on Thursday, February 13th. The company reported $1.40 earnings per share for the quarter, topping analysts' consensus estimates of $1.37 by $0.03. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. The firm had revenue of $2.32 billion for the quarter, compared to the consensus estimate of $2.30 billion. Analysts predict that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be issued a $0.50 dividend. The ex-dividend date is Monday, April 21st. This represents a $2.00 annualized dividend and a dividend yield of 1.32%. Zoetis's dividend payout ratio is currently 36.56%.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.